
ACT Brief: AI Trial Matching Access, IRB Oncology Expertise, and Livsayis Myasthenia Gravis Approval
In today’s ACT Brief, we examine why AI-enabled trial matching could close the oncology access gap, why IRBs need substantive therapeutic expertise, and how FDA approved Regeneron’s Livsayis, a treatment given four times a year for myasthenia gravis.



















